Immunostimulatory Fusion Molecule Targeting T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cytokines used in cancer therapy face challenges due to rapid blood clearance and lack of tumor specificity, requiring high systemic doses that lead to severe toxicity and adverse reactions.
Innovation Solution
Development of an immunostimulatory fusion molecule comprising an immune stimulating cytokine molecule operably linked with an immune cell targeting moiety, such as an antigen-binding fragment of an antibody, to specifically target immune cells like T cells, enhancing localized immune response while reducing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high systemic doses of cytokine are administered to achieve sufficient concentration at tumor site, then therapeutic effectiveness is improved, but toxicity and adverse reactions increase
Solution Approach 1:
The cytokine is conjugated to a tumor-targeting antibody, creating a fusion molecule with heterogeneous distribution properties. The cytokine component remains inactive until it reaches the tumor microenvironment where the antibody component binds to tumor-specific antigens, enabling localized cytokine activation and effect at the tumor site while minimizing systemic exposure and toxicity
Solution Approach 2:
The antibody component serves as an intermediary that selectively delivers the cytokine to tumor cells. The antibody binds to tumor-specific antigens with high affinity, acting as a targeted delivery vehicle that concentrates the cytokine at the tumor site and facilitates its local activation, thereby achieving therapeutic effectiveness without requiring high systemic doses
2Reliability
If high systemic doses of cytokine are administered to overcome rapid blood clearance, then therapeutic effectiveness is improved, but severity of side effects increases
Solution Approach 1:
The fusion molecule exhibits spatially heterogeneous activity: the cytokine component is sequestered in the circulation in an inactive state bound to the antibody, then activated locally at the tumor site where the antibody-tumor antigen complex forms. This local activation mechanism ensures reliable therapeutic effect at the tumor while minimizing systemic adverse reactions
Solution Approach 2:
The antibody component performs preliminary targeted delivery of the cytokine to the tumor site before cytokine activation occurs. This preliminary targeting action ensures that the cytokine is already positioned at the tumor microenvironment when activated, maximizing therapeutic effectiveness while avoiding premature systemic activation and associated side effects
3Reliability
If systemic administration of cytokine is used to achieve tumor specificity, then anti-tumor effect is improved, but destruction of non-tumor cells occurs
Solution Approach 1:
The fusion molecule creates localized cytokine activity exclusively at the tumor site through antibody-mediated targeting. The cytokine component activates immune responses only where the antibody binds to tumor-specific antigens, producing potent anti-tumor effects while sparing non-tumor cells from cytokine-mediated destruction
Solution Approach 2:
The antibody acts as a selective intermediary that mediates between the cytokine and tumor cells. It confers tumor specificity to the otherwise non-specific cytokine, directing the anti-tumor effect precisely to tumor cells expressing the target antigen while preventing off-target effects on healthy tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion molecule achieves targeted immune stimulation with reduced side effects by increasing cytokine concentration and availability on immune cells, prolonging signaling, and enhancing immune response against cancer cells.
Implementation Method 1
an immune cell targeting moiety comprising an antigen-binding fragment of an antibody having an affinity to an antigen on the surface of a target immune cell
Data Source
AI summary
Immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule, pharmaceutical and formulations thereof, and methods of using and making the same, are disclosed.